Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin after mechanical thrombectomy for large vessel occlusion stroke
PACTR202306562134107Completed
- Sponsor
- Ain Shams University Hospitals
- Start
- Apr 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Open-label trial of cerebrolysin in ischemic stroke, cardioembolic stroke and Large-Vessel Ischemic Stroke (LVO) (2 arms), sponsored by Ain Shams University Hospitals. Primary endpoint: Favorable functional outcome at 90 days. Started Apr 2024; status: completed.
02
Drugs
cerebrolysin
03
Conditions
ischemic strokecardioembolic strokeLarge-Vessel Ischemic Stroke (LVO)
Beyond the preview
Go deeper on PACTR202306562134107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202306562134107.